Ori Biotech

Introducing IRO®, the new standard in CGT manufacturing technology. 🎉 Manufacturing remains a critical barrier to scaling cell and gene therapies – making it difficult to meet the patient need, and limiting the clinical and commercial impact of this new class of therapies. That’s why we developed IRO®. IRO® combines an efficient and flexible platform with a scalable, digital solution to industrialize precision medicine manufacturing – delivering a seamless transition from R&D into the clinic, and from clinical scale to commercial scale. By empowering scientists with tools that help accelerate product development and Automate Better Biology, we are working to help enable widespread patient access and scale the impact of life-changing cell and gene therapies. Thank you to everyone who attended our launch at ISCT today. It's an incredibly exciting moment to finally unveil our work over the past 5-years – we are very grateful to the Ori team and our partners for helping us achieve this milestone. Read our full press release: https://lnkd.in/eT3B3MSf Schedule a hands on demo to see how IRO® could work for you: https://lnkd.in/eXEXEGZZ #ISCT2024 #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #Biotechnology

🔬“It was kinda my last hope.” - Shannon Findley In 2020, Shannon faced a difficult battle with lymphoma. After multiple rounds of chemotherapy failed, she turned to CAR-T therapy in 2022 as a last resort. Just 30 days later, her cancer stabilized, and a year on, Shannon achieved full remission. Now, she cherishes time with her grandchildren, gardening and even fulfilled her dream of assisting University of Tennessee, Knoxville’s softball coach. Thank you WZTV for sharing Shannon’s incredible journey ➡️ https://lnkd.in/ebXrKADj #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

We recently hosted a successful The CGT Circle Event with PA Consulting in Philadelphia, bringing together women across the CGT sector to discuss practical networking strategies and share valuable insights with other leaders in the industry. Here are our key takeaways from the panel: 🤝 Networking is a two-way street – many leaders actively network to share knowledge with the next generation 🤝 Energy management matters – positioning yourself in high-traffic areas can lead to unexpected connections, but don’t forget to recharge your social batteries when needed 🤝 Cultivate genuine connections – building genuine relationships with peers is just as important as connecting with industry leaders Missed it? Feel free to reach out to Kara Win and Niamh O'Connell with any questions or drop a comment below ⬇️ #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

🔬 The path to accessible, affordable cell and gene therapies isn’t only about clinical breakthroughs. Each step – from manufacturing to payer strategies – needs careful optimization. In the first of a five part series – co-authored by our CEO Jason C. Foster, @Molly Borchardt at Precision AQ, Philip Cyr at Precision AQ, and Erin Lopata at Precision AQ and published on CGTLive – examines manufacturing challenges and their impact on patient access. Key takeaways include: 🔹 Autologous cell and gene therapies hold great promise, but their high costs present a significant barrier to widespread access 🔹 Patients face not only financial hurdles but also nonmonetary challenges, such as delayed diagnoses, limited access to specialized care, and considerable travel and lodging expenses 🔹 Payers remain concerned about the long-term efficacy of these therapies, complicating decisions on coverage and affordability, especially in light of limited data on patient outcomes Read the first part In a five-part series in CGTLive examining the manufacturing and market access challenges that currently limit patient access to cell and gene therapies ⬇️ https://lnkd.in/eUUaczH8 #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

How can data integration and decentralized manufacturing improve access to cell and gene therapies? Join Amritha J., Executive Director at IQVIA's Cell and Gene Therapy Center and Ori Biotech's CEO, Jason C. Foster, on the latest episode of the Ori Spotlight podcast. With her extensive experience in life sciences, Amritha shares her perspectives on the current landscape of cell and gene therapy, highlighting the complexities around data integration, decentralized manufacturing and patient access. Amritha and Jason also explore how addressing these challenges early in the development process can improve scalability, reduce costs and ultimately drive better outcomes for patients worldwide. 🎧 Listen to the Ori Spotlight podcast now: https://lnkd.in/eR6DyG2E #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

Heading to the J.P. Morgan Healthcare Conference this January? Ori Biotech’s CEO, Jason C. Foster, will be in San Francisco from 13-16 January, exploring how technology and automation is setting the new standard in cell and gene therapy manufacturing. Here's where you can find him 👇 📌 Biotech Showcase 📅 Jan 13, 10:00 AM 📍 Hilton Union Square 🎙️ Company presentation: Ori Biotech's strategic partnerships and innovations in biotechnology 📌 Endpoints News Hub 📅 Jan 14, 8:40 AM 📍 Marriott Marquis 🎙️ Fireside Chat: "Decentralized Manufacturing: A New Era for CAR-T Cell Therapy" Interested in a one-on-one meeting with Jason? Connect with him to learn how IRO® helps to scale the impact of cell and gene therapies. 🔍 Learn more about IRO ➡️ https://lnkd.in/evCqHZnB #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact #JPM2025

🔬 Imagine being told you have just two weeks to live. That was Lisa Noble’s reality in 2020… After four rounds of chemotherapy failed to successfully treat her B cell lymphoma, Lisa’s final hope was CAR-T cell therapy at Addenbrooke’s Hospital in Cambridge. Three months after receiving CAR-T, she was cancer-free – and still is today. “It’s amazing. I wouldn’t have been able to celebrate my 25th wedding anniversary or see three of my grandchildren born without it,” she shared. For patients like Lisa, CAR-T is a life-saving treatment and Cambridge's new Cellular Therapy Lab promises to make these therapies more accessible, giving more patients the chance to rewrite their stories. Thank you BBC News for sharing Lisa’s incredible journey ➡️ https://lnkd.in/ep9buQJB #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

⚙️ Do we need to rethink manufacturing processes? Refining core manufacturing processes early helps ensure therapies are commercially viable and scalable. In fact, according to Ori CEO Jason C. Foster, it's this process optimization that enables successful CDMO partnerships. Jason and Anshul Mangal, President at Project Farma (PF), discussed that being proactive about investing in efficient, automated systems from the beginning of product development can accelerate timelines and reduce costs – all without compromising quality. 🎧 Listen to the Ori Spotlight podcast now: https://lnkd.in/e9YyJeCm #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

🎉 We've won the 2024 BioTech Breakthrough CGT Innovation Award! This award honors innovation in biotechnology, highlighting companies, services and products that are setting new standards and making a meaningful difference worldwide. The award recognizes Ori’s IRO® platform, which is designed to provide superior biological performance, accelerate therapy development and scale the clinical and commercial impact of these life-saving cell therapies. We’re honored to be recognized for our work in transforming CGT manufacturing. A huge thank you to our incredible team, partners, and supporters who make our mission possible! Learn more: https://lnkd.in/eBFYWEtB #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact 

“As the advanced therapy sector approaches a critical juncture in its growth, the industry’s ability to navigate these challenges will define its trajectory and potential to revolutionize treatment paradigms.” – Deloitte’s 2024 Advanced Therapy Industry Report Examining the current landscape of cell and gene therapy, with input from 376 respondents across the ecosystem, Deloitte's report identifies both challenges and opportunities across research, development, manufacturing, commercialization and patient access. Key insights from the report include: ⚙️Over 40% of industry leaders are unsure about meeting the future demand for advanced therapies ⚙️Nearly 90% of therapy developers are now collaborating with external manufacturers to accelerate the path to market ⚙️Payer and reimbursement issues remain a top concern for the commercialization of advanced therapies We’ve summarized the key takeaways ⬇️ Download the full report: https://lnkd.in/eDFPAutA #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology